



## **Prof. Dr. med.; M.Sc. Michael Brändle**

Allgemeine Innere Medizin | Hausarztmedizin, Endokrinologie | Diabetologie |  
Osteologie | Stoffwechselerkrankungen · Dept. I

### **Contact**

Prof. Dr. med.; M.Sc. Michael Brändle  
Rorschacherstrasse 95  
9007 St. Gallen  
Switzerland

T +41 71 494 1001  
Michael.Braendle@kssg.ch

### **Homepage**

[www.endocrinology.ch](http://www.endocrinology.ch)

### **Units**

Allgemeine Innere Medizin | Hausarztmedizin, Endokrinologie | Diabetologie | Osteologie | Stoffwechselerkrankungen

## Publications (138)

Baumgartner A, Olpe T, Griot S, Mentil N, Staub N, Burn F, Schindera S, Kaegi-Braun N, Tribolet P, Hoess C, Pavlicek V, Bilz S, Sigrist S, Brändle M, Henzen C, Thomann R, Rutishauser J, Aujesky D, Rodondi N, Donzé J, Stanga Z, Mueller B, Schuetz P. Association of CT-based diagnosis of sarcopenia with prognosis and treatment response in patients at risk of malnutrition – A secondary analysis of the Effect of early nutritional support on Frailty, Functional Outcomes, and Recovery of malnourished medical inpatients Trial (EFFORT) trial. *Clin Nutr* 2022; 42:199–207.

Boesing M, Abig K, Brändle M, Brutsche M, Burri E, Frye B, Giezendanner S, Grutters J, Haas P, Heisler J, Jaun F, Leuppi-Taegtmeier A, Lüthi-Corridori G, Müller-Quernheim J, Nüesch R, Pohl W, Rassouli F, Leuppi J. Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol for a randomized, placebo-controlled, and multicenter trial. *Trials* 2022; 23:790.

Koster M, Brändle M. Hyperkalzämie – Diagnose, Abklärung und Therapie. *Praxis* 2022

Koster M, Brändle M. [Hypercalcemia - Diagnosis and Management]. *Praxis (Bern 1994)* 2022; 111:675–681.

Christ E, Czock A, Renström F, Ammeter T, Ebrahimi F, Zechmann S, Kutz A, Diem P, Häuptle C, Brändle M. Evaluation of type 2 diabetes care management in nine primary care practices before and after implementation of the Criteria of Good Disease Management of Diabetes established by the Swiss Society of Endocrinology and Diabetology. *Swiss Med Wkly* 2022; 152:w30197.

Stalder L, Kaegi-Braun N, Gressies C, Gregoriano C, Tribolet P, Lobo D, Gomes F, Hoess C, Pavlicek V, Bilz S, Sigrist S, Brändle M, Henzen C, Thomann R, Rutishauser J, Aujesky D, Rodondi N, Donzé J, Stanga Z, Mueller B, Schuetz P. Prospective validation of five malnutrition screening and assessment instruments among medical inpatients: Secondary analysis of a randomized clinical trial. *Clin Nutr* 2022; 41:1307–1315.

Kaegi-Braun N, Boesiger F, Tribolet P, Gomes F, Kutz A, Hoess C, Pavlicek V, Bilz S, Sigrist S, Brändle M, Henzen C, Thomann R, Rutishauser J, Aujesky D, Rodondi N, Donzé J, Stanga Z, Lobo D, Cederholm T, Mueller B, Schuetz P. Validation of modified GLIM criteria to predict adverse clinical outcome and response to nutritional treatment: A secondary analysis of a randomized clinical trial. *Clin Nutr* 2022; 41:795–804.

Bretschera C, Boesiger F, Kaegi-Braun N, Hersberger L, Lobo D, Evans D, Tribolet P, Gomes F, Hoess C, Pavlicek V, Bilz S, Sigrist S, Brändle M, Henzen C, Thomann R, Rutishauser J, Aujesky D, Rodondi N, Donzé J, Stanga Z, Mueller B, Schuetz P. Admission serum albumin concentrations and response to nutritional therapy in hospitalised patients at malnutrition risk: Secondary analysis of a randomised clinical trial. *EClinicalMedicine* 2022; 45:101301.

Jaun F, Boesing M, Lüthi-Corridori G, Abig K, Makhdoomi A, Bloch N, Lins C, Raess A, Grillmayr V, Haas P, Schuetz P, Gabutti L, Muser J, Leuppi-Taegtmeier A, Giezendanner S, Brändle M, Leuppi J. High-dose vitamin D substitution in patients with COVID-19: study protocol for a randomized, double-blind, placebo-controlled, multi-center study-VitCov Trial. *Trials* 2022; 23:114.

Kaegi-Braun N, Tribolet P, Baumgartner A, Fehr R, Baechli V, Geiser M, Deiss M, Gomes F, Kutz A, Hoess C, Pavlicek V, Schmid S, Bilz S, Sigrist S, Brändle M, Benz C, Henzen C, Thomann R, Rutishauser J, Aujesky D, Rodondi N, Donzé J, Stanga Z, Mueller B, Schuetz P. Value of handgrip strength to predict clinical outcomes and therapeutic response in malnourished medical inpatients: Secondary analysis of a randomized controlled trial. *Am J Clin Nutr* 2021; 114:731–740.

Eichmüller T, Renström F, Schimke K, Brändle M. Representativeness of the Swiss Diabetes Registry – a single centre analysis. *Swiss Med Wkly* 2021; 151:w20525.

Hersberger L, Dietz A, Bürgler H, Bargetzi A, Bargetzi L, Kägi-Braun N, Tribolet P, Gomes F, Hoess C, Pavlicek V, Bilz S, Sigrist S, Brändle M, Henzen C, Thomann R, Rutishauser J, Aujesky D, Rodondi N, Donzé J, Stanga Z, Mueller B, Schuetz P. Individualized Nutritional Support for Hospitalized Patients With Chronic Heart Failure. *J Am Coll Cardiol* 2021; 77:2307-2319.

Baumgartner A, Brändle M, Henzen C, Thomann R, Rutishauser J, Aujesky D, Rodondi N, Donzé J, Stanga Z, Mueller B, Sigrist S, Bilz S, Pavlicek V, Pachnis D, Parra L, Hersberger L, Bargetzi A, Bargetzi L, Kaegi-Braun N, Tribolet P, Gomes F, Hoess C, Schuetz P. The impact of nutritional support on malnourished inpatients with aging-related vulnerability. *Nutrition* 2021; 89:111279.

Bargetzi A, Emmenegger N, Wildisen S, Nickler M, Bargetzi L, Hersberger L, Segerer S, Kaegi-Braun N, Tribolet P, Gomes F, Hoess C, Pavlicek V, Bilz S, Sigrist S, Brändle M, Henzen C, Thomann R, Rutishauser J, Aujesky D, Rodondi N, Donzé J, Stanga Z, Mueller B, Schuetz P. Admission kidney function is a strong predictor for the response to nutritional support in patients at nutritional risk. *Clin Nutr* 2021; 40:2762-2771.

Blum D, de Wolf-Linder S, Oberholzer R, Brändle M, Hundsberger T, Strasser F. Natural ghrelin in advanced cancer patients with cachexia, a case series. *J Cachexia Sarcopenia Muscle* 2021; 12:506-516.

Baumgartner A, Hasenboehler F, Cantone J, Hersberger L, Bargetzi A, Bargetzi L, Kaegi-Braun N, Tribolet P, Gomes F, Hoess C, Pavlicek V, Bilz S, Sigrist S, Brändle M, Henzen C, Thomann R, Rutishauser J, Aujesky D, Rodondi N, Donzé J, Stanga Z, Mueller B, Schuetz P. Effect of nutritional support in patients with lower respiratory tract infection: Secondary analysis of a randomized clinical trial. *Clin Nutr* 2020; 40:1843-1850.

Kaegi-Braun N, Brändle M, Benz C, Henzen C, Mattmann S, Thomann R, Rutishauser J, Aujesky D, Rodondi N, Donzé J, Stanga Z, Mueller B, Sigrist S, Bilz S, Tribolet P, Gomes F, Fehr R, Baechli V, Geiser M, Deiss M, Kutz A, Bregenzler T, Hoess C, Pavlicek V, Schmid S, Schuetz P. Six-month outcomes after individualized nutritional support during the hospital stay in medical patients at nutritional risk: Secondary analysis of a prospective randomized trial. *Clin Nutr* 2020

Schoeb M, Räss A, Frei N, Aczel S, Brändle M, Bilz S. High Risk of Hypophosphatemia in Patients with Previous Bariatric Surgery Receiving Ferric Carboxymaltose: A Prospective Cohort Study. *Obes Surg* 2020; 30:2659-2666.

Zumbrunn B, Vollenweider P, Reny J, Petignat P, Huber L, Henzen C, Hayoz D, Genné D, Brändle M, Beer J, Battegay E, Bassetti S, Ballmer P, Limacher A, Stalder O, Aujesky D. The well-being of Swiss general internal medicine residents. *Swiss Med Wkly* 2020; 150:w20255.

Merker M, Henzen C, Thomann R, Rutishauser J, Aujesky D, Rodondi N, Donzé J, Stanga Z, Mueller B, Brändle M, Sigrist S, Bilz S, Felder M, Gueissaz L, Bolliger R, Tribolet P, Kägi-Braun N, Gomes F, Hoess C, Pavlicek V, Schuetz P. Association of Baseline Inflammation With Effectiveness of Nutritional Support Among Patients With Disease-Related Malnutrition: A Secondary Analysis of a Randomized Clinical Trial. *JAMA Netw Open* 2020; 3:e200663.

Hersberger L, Brändle M, Benz C, Henzen C, Nigg M, Thomann R, Brand C, Rutishauser J, Aujesky D, Rodondi N, Donzé J, Stanga Z, Mueller B, Sigrist S, Bilz S, Schmid S, Bargetzi L, Bargetzi A, Tribolet P, Fehr R, Baechli V, Geiser M, Deiss M, Gomes F, Kutz A, Kägi-Braun N, Hoess C, Pavlicek V, Schuetz P. Nutritional risk screening (NRS 2002) is a strong and modifiable predictor risk score for short-term and long-term clinical outcomes: secondary analysis of a prospective randomised trial. *Clin Nutr* 2019; 39:2720-2729.

Brändle M. Polyglobulie bei Missbrauch von androgenen anabolen Steroiden - Was hat «Das Schwarze Buch» mit Aderlass zu tun?. *Swiss Med Forum* 2019; 19:655-658.

Merker M, Henzen C, Thomann R, Rutishauser J, Aujesky D, Rodondi N, Donzé J, Stanga Z, Mueller B, Brändle M, Sigrist S, Amsler A, Pereira R, Bolliger R, Tribolet P, Braun N, Hoess C, Pavlicek V, Bilz S, Schuetz P. Vitamin D deficiency is highly prevalent in malnourished inpatients and associated with higher mortality: A prospective cohort study. *Medicine (Baltimore)* 2019; 98:e18113.

Wiesli P, Pavlicek V, Brändle M, Pfammatter T, Perren A, Schmid C. Distinct mechanisms of hypoglycaemia in patients with somatostatin-secreting neuroendocrine tumours. *Endocrinol Diabetes Metab* 2019; 2:e00083.

Schuetz P, Brändle M, Benz C, Henzen C, Mattmann S, Thomann R, Brand C, Rutishauser J, Aujesky D, Rodondi N, Donzé J, Stanga Z, Sigrist S, Bilz S, Schmid S, Fehr R, Baechli V, Geiser M, Deiss M, Gomes F, Kutz A, Tribolet P, Bregenzer T, Braun N, Hoess C, Pavlicek V, Mueller B. Individualised nutritional support in medical inpatients at nutritional risk: a randomised clinical trial. *Lancet* 2019; 393:2312-2321.

Koster M, Ritter S, Brändle M. [Rapid Resolution of Symptomatic Hypercalcaemia]. *Praxis (Bern 1994)* 2019; 108:495-498.

Beglinger C, Kim M, Tsinalis D, Enzler-Tschudy A, Jung K, Brändle M, Binet F. Vitamin-D-Intoxikation als seltene Ursache einer schweren Hyperkalzämie - Wenn YouTube alles besser weiss .... *Swiss Med Forum* 2018; 18:796-799.

Schöb M, Müller P, Gerth Y, Korte W, Rickli H, Brändle M, Bärlocher A, Bilz S. [Diagnosis and Treatment of Familial Hypercholesterolemia]. *Praxis (Bern 1994)* 2018; 107:1345-1353.

Danne T, Sawhney S, Peters A, McGuire D, Lapuerta P, Kushner J, Franek E, Brath H, Brändle M, Banks P, Cariou B, Strumph P. HbA and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study. *Diabetes care* 2018; 41:1981-1990.

Herman W, Braffett B, Kuo S, Lee J, Brändle M, Jacobson A, Prosser L, Lachin J. What are the clinical, quality-of-life, and cost consequences of 30 years of excellent vs. poor glycemic control in type 1 diabetes?. *J Diabetes Complicat* 2018; 32:911-915.

Herman W, Braffett B, Kuo S, Lee J, Brändle M, Jacobson A, Prosser L, Lachin J. The 30-year cost-effectiveness of alternative strategies to achieve excellent glycemic control in type 1 diabetes: An economic simulation informed by the results of the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC). *J Diabetes Complicat* 2018; 32:934-939.

Palmer A, Gahn J, Valentine W, Pollock R, Breeze P, Brennan A, Pollard D, Ye W, Herman W, Isaman D, Kuo S, Laiteerapong N, Tran-Duy A, Smolen H, Brändle M, Si L, Tew M, Hua X, Willis M, Asseburg C, McEwan P, Leal J, Gray A, Foon V, Lamotte M, Feenstra T, O'Connor P, Clarke P. Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge. *Value Health* 2018; 21:724-731.

Schimke K, Renström F, Meier S, Stettler C, Brändle M, SwissDiab Study Group. Compliance with guidelines for disease management in diabetes: results from the SwissDiab Registry. *BMJ Open Diabetes Res Care* 2018; 6:e000454.

Iacovazzo D, Jenni S, Sipos B, Nieser M, Frilling A, Dhatriya K, Chanson P, de Herder W, Konukiewitz B, Klöppel G, Stein R, Korbonits M, Christ E, Niederle B, Flanagan S, Walker E, Quezado R, de Sousa Barros F, Caswell R, Johnson M, Wakeling M, Brändle M, Guo M, Dang M, Gabrovská P, Ellard S. missense mutation causes familial insulinomatosis and diabetes mellitus. *Proc Natl Acad Sci USA* 2018; 115:1027-1032.

Quarella M, Walser D, Brändle M, Fournier J, Bilz S. Rapid Onset of Diabetic Ketoacidosis After SGLT2 Inhibition in a Patient With Unrecognized Acromegaly. *J Clin Endocrinol Metab* 2017; 102:1451-1453.

Brändle M, Büche D, Nestor K. Hilfe beim Sterben, Hilfe zum Sterben oder Hilfe zum Leben? – Sterbehilfe rechtlich, ethisch und palliativ betrachtet. *Schweiz Med Forum* 2017; 17:738–743.

Streuli R, Krull I, Brändle M, Kolb W, Stalla G, Theodoropoulou M,ENZLER-Tschudy A, Bilz S. A rare case of an ACTH/CRH co-secreting midgut neuroendocrine tumor mimicking Cushing's disease. *Endocrinol Diabetes Metab Case Rep* 2017; 2017

Anthony D, Diethelm M, Brändle M. Schweres SIRS bei Rheumatoider Arthritis – auch an seltene Ursachen denken!. *Praxis (Bern 1994)* 2016; 105:1147–50.

Koster-Rusch A, Capraro J, Nagel W, Clerici T, Stöckli S, Forrer F, Brändle M, Bilz S. Bilaterale Halsschwellung bei einer jungen Frau. *Swiss Medical Forum* 2016; 16:253–255.

Huber C, Brändle M, Rapold R, Reich O, Rosemann T. A set of four simple performance measures reflecting adherence to guidelines predicts hospitalization: a claims-based cohort study of patients with diabetes. *Patient Prefer Adherence* 2016; 10:223–31.

Trombetti A, Rizzoli R, Kraenzlin M, Triponez F, Torriani C, Herrmann F, Brändle M, Gold G, Henzen C, Christ E, Meier C. Clinical presentation and management of patients with primary hyperparathyroidism of the Swiss Primary Hyperparathyroidism Cohort: a focus on neuro-behavioral and cognitive symptoms. *J Endocrinol Invest* 2016; 39:567–76.

Gerber P, Spinas G, Brändle M, Oberkofler C, Kron P, Ajdler-Schaeffler E, Tschopp O, Zuellig R, Locher R, Lehmann R. Glycemia, Hypoglycemia, and Costs of Simultaneous Islet-Kidney or Islet After Kidney Transplantation Versus Intensive Insulin Therapy and Waiting List for Islet Transplantation. *Transplantation* 2015; 99:2174–80.

Brändle M. Hyperglykämische Notfallsituationen beim Erwachsenen – Diabetische Ketoazidose und hyperosmolare hyperglykämie Entgleisung. *Swiss Medical Forum* 2015; 15:723–728.

Ye W, Brändle M, Brown M, Herman W. The Michigan Model for Coronary Heart Disease in Type 2 Diabetes: Development and Validation. *Diabetes Technol Ther* 2015; 17:701–11.

Grouzmann E, Fischli S, Henzen C, Zulewski H, Sigrist S, Drescher T, Brändle M, Bilz S, Matter M, Triponez F, Tschopp O, Abid K. Catecholamine metabolism in paraganglioma and pheochromocytoma: similar tumors in different sites?. *PloS one* 2015; 10:e0125426.

Brändle M. Was ist die Ursache der Hyponatriämie?. *Swiss Medical Forum* 2015; 15

Valentine W, Curtis B, Pollock R, Van Brunt K, Paczkowski R, Brändle M, Boye K, Kendall D. Is the current standard of care leading to cost-effective outcomes for patients with type 2 diabetes requiring insulin? A long-term health economic analysis for the UK. *Diabetes Res Clin Pract* 2015; 109:95–103.

Brändle M. Ein Sturz mit Folgen – Posttraumatischer Panhypopituitarismus. *Swiss Medical Forum* 2015; 15:303–305.

Lipowsky C, Sze L, Krull I, Brändle M. Liraglutide as add-on therapy to insulin in type 2 diabetes mellitus: a retrospective, observational study from a daily clinical practice setting in Switzerland. *Diabetes Ther* 2015; 6:41–7.

Niederer-Wuest S, Stöckli S, ess s, Haile S, Müller J, Oettli R, Clerici T, Bilz S, Brändle M, Förbs D, Jochum W, Broglie Däppen M. Impact of clinical risk scores and BRAF V600E mutation status on outcome in papillary thyroid cancer. *Surgery* 2015; 157:119-25.

Schmid S, Rothermundt C, Weber J, van Leyen K, Sulz M, Stöckli S, Krull I, Krek W, Kloos P, Heinemann K, Hader C, Greiner J, Engeler D, Brändle M, Binet F, Gillessen Sommer S, Hundsberger T. Management of von Hippel-Lindau Disease: An Interdisciplinary Review. *Oncol Res Treat* 2014; 37:761-771.

Faeh D, Marques-Vidal P, Brändle M, Braun J, Rohrmann S. Diabetes risk scores and death: predictability and practicability in two different populations. *Eur J Public Health* 2014; 25:26-8.

Smith-Palmer J, Brändle M, Trevisan R, Orsini Federici M, Liabat S, Valentine W. Assessment of the association between glycemic variability and diabetes-related complications in type 1 and type 2 diabetes. *Diabetes Res Clin Pract* 2014; 105:273-84.

Schmid S, Fornaro J, Rothermundt C, Omlin A, Brändle M, Rupp N, Gillessen Sommer S. Abiraterone--what is wrong with the adrenal glands?. *Clin Genitourin Cancer* 2014; 12:e133-7.

Sze L, Neidert M, Bernays R, Zwimpfer C, Wiesli P, Haile S, Brändle M, Schmid C. Gender dependence of serum soluble Klotho in acromegaly. *Clin Endocrinol (Oxf)* 2014; 80:869-73.

Brändle M. Von Myopie zu Hyperopie in drei Wochen – ohne Brillenkorrektur. *Swiss Medical Forum* 2013; 13:758-760.

Krull I, Brändle M. Hyperthyreose: Diagnostik und Therapie. *Swiss Medical Forum* 2013; 13:954-960.

Sze L, Bernays R, Zwimpfer C, Wiesli P, Brändle M, Schmid C. Impact of Growth Hormone on Cystatin C. *Nephron Extra* 2013; 3:118-124.

Christ E, Reubi J, Perren A, Gloor B, Seufert J, Ell P, Stettler C, Fischli S, Clerici T, Brändle M, Caplin M, Nicolas G, Béhé M, Ederer S, Wild D, Forrer F. Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study. *Lancet Diabetes Endocrinol* 2013; 1:115-22.

Gozzi Graf T, Brändle M, Clerici T, L'allemand D. Insulinoma: only in adults?--case reports and literature review. *Eur J Pediatr* 2013; 173:567-74.

Gnädinger M, Clerici T, Brändle M, Mellinghoff H. Diagnostische und therapeutische Aspekte des Vitamin-D-Mangels bei Patienten mit primärem Hyperparathyreoidismus. *Swiss Medical Forum* 2012; 12:659-660.

Hildebrandt G, Brändle M, Stienen M, Gautschi O, van Leyen K. Post-surgical obesity in 3rd ventricular tumours – new pathophysiological perspectives. *Chirurgia* 2012; 25:301-310.

Sze L, Bernays R, Zwimpfer C, Wiesli P, Brändle M, Schmid C. Excessively high soluble Klotho in patients with acromegaly. *J Intern Med* 2012; 272:93-7.

Valentine W, Palmer A, Lammert M, Langer J, Brändle M. Evaluating the Long-Term Cost-Effectiveness of Liraglutide Versus Exenatide BID in Patients With Type 2 Diabetes Who Fail to Improve With Oral Antidiabetic Agents. *Clin Ther* 2011; 33:1698-712.

Gerber P, Spirk D, Brändle M, Thoenes M, Lehmann R, Keller U. Regional differences of glycaemic control in patients with type 2 diabetes mellitus in Switzerland: a national cross-sectional survey. *Swiss Med Wkly* 2011; 141:w13218.

Hegar K, Heiber S, Brändle M, Christ E, Keller U. Carbohydrate counting of food. *Swiss Med Wkly* 2011; 141:w13224.

Wild D, Eil P, Perren A, Bomanji J, Weber W, Seufert J, Brändle M, Forrer F, Kurzwinski T, Caplin M, Christ E, Reubi J. Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. *J Nucl Med* 2011; 52:1073-8.

Brändle M, Azoulay M, Greiner R. Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland. *Int J Clin Pharmacol Ther* 2011; 49:217-230.

Brändle M. Diabetes - Patient Selection. In: *Textbook of Interventional Cardiology*. 6th Edition Philadelphia: Elsevier Saunders, 2011. ISBN 978-1-4377-2358-8. pp. 30-50.

Pollock R, Valentine W, Goodall G, Brändle M. Evaluating the cost-effectiveness of self-monitoring of blood glucose in type 2 diabetes patients on oral anti-diabetic agents. *Swiss Med Wkly* 2010; 140:w13103.

Möller-Goede D, Brändle M, Landau K, Bernays R, Schmid C. Pituitary apoplexy: re-evaluation of risk factors for bleeding into pituitary adenomas and impact on outcome. *Eur J Endocrinol* 2010; 164:37-43.

Steffen T, Warschkow R, Brändle M, Tarantino I, Clerici T. Randomized controlled trial of bilateral superficial cervical plexus block versus placebo in thyroid surgery. *Br J Surg* 2010; 97:1000-6.

Böhm S, Hess D, Gillessen Sommer S, Brändle M. Improved glycemic control with the multi-receptor tyrosine kinase inhibitor pazopanib. *Diabetes care* 2010; 33:e82.

Krull I, Maier M, Bärlocher K, Koehler K, Huebner A, Brändle M. Two patients with an identical novel mutation in the AAAS gene and similar phenotype of triple A (Allgrove) syndrome. *Exp Clin Endocrinol Diabetes* 2010; 118:530-6.

Brändle M. Therapie des Diabetes mellitus Typ 2 mit bariatrischer Chirurgie - Contra - eine kritische Beurteilung. *Swiss Medical Forum* 2010; 10:88-91.

Schimke K, Greminger P, Brändle M. Secondary adrenal insufficiency due to opiate therapy - another differential diagnosis worth consideration. *Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association* 2009; 117:649-51.

Christ E, Maecke H, Martius F, Gloor B, Clerici T, Sahli R, Brändle M, Forrer F, Wild D, Reubi J. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. *The Journal of clinical endocrinology and metabolism* 2009; 94:4398-405.

Lehmann R, Troendle A, Brändle M, Schweizerischen Gesellschaft für Endokrinologie und Diabetologie. [New insights into diagnosis and management of gestational diabetes mellitus: recommendations of the Swiss Society for Endocrinology and Diabetes]. *Therapeutische Umschau. Revue thérapeutique* 2009; 66:695-706.

Brändle M, Erny-Albrecht K, Goodall G, Spinas G, Streit P, Valentine W. Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland. *International journal of clinical pharmacology and therapeutics* 2009; 47:501-15.

Goede D, Wiesli P, Brändle M, Bestmann L, Bernays R, Zwimpfer C, Schmid C. Effects of thyroxine replacement on serum creatinine and cystatin C in patients with primary and central hypothyroidism. *Swiss medical weekly : official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology* 2009; 139:339-44.

Bühler-Christen A, Tischler V, Diener P, Brändle M. New onset alopecia and hirsutism in a postmenopausal women. *Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology* 2009; 25:324-7.

Brändle M, Goodall G, Erny-Albrecht K, Erdmann E, Valentine W. Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting. *Swiss medical weekly : official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology* 2009; 139:173-84.

Marre M, Colagiuri S, Le Thi T, Zdravkovic M, Strand J, Kamaruddin N, Bebakar W, Brändle M, Shaw J, LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). *Diabetic medicine : a journal of the British Diabetic Association* 2009; 26:268-78.

Phillippe J, Weissenberger B, Stahl M, Ruiz J, Kuntschen F, Keller U, Diem P, Carrel J, Brändle M, Spinas G. Massnahmen zur Blutzuckerkontrolle bei Patienten mit Typ-2-Diabetes-mellitus - Consensus Statement der Schweizerischen Gesellschaft für Endokrinologie. *Swiss Medical Forum* 2009; 9:50-55.

Templeton A, Brändle M, Cerny T, Gillessen Sommer S. Remission of diabetes while on sunitinib treatment for renal cell carcinoma. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2008; 19:824-5.

Strasser F, Cerny T, Von Moss R, Brändle M, Holst B, Kaufmann K, Tschöp M, Büche D, Thürlimann B, Maeder M, Lutz T, Demmer-Steingruber R. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. *BJC* 2008; 98:300-8.

Lipowsky C, Schorl-Schweikardt B, Kehl O, Brändle M. [19-year-old patient with adrenal cortex insufficiency--only the tip of the iceberg. Polyendocrine autoimmune syndrome type II (Schmidt syndrome)]. *Praxis* 2008; 97:77-81.

Brändle M. Cost analysis of diabetes and pregnancy. In: *Textbook of Diabetes and Pregnancy*. 2nd Edition London, England: Informa Health Care, 2008. ISBN 978 0 415 42620 6. pp. 392-398.

Preusser S, Diener P, l'Allemand-Jander D, Schmid S, Leippold T, Brändle M, Schmid H. Scrotal hysterectomy in a male patient with mixed gonadal dysgenesis 46,XY(75%)/45,X(25%). *Urology* 2007; 70:1223.e7-9.

Clerici T, Warschkow R, Triponez F, Brändle M. National survey on the management of primary hyperparathyroidism by Swiss endocrinologists. *Langenbeck's archives of surgery / Deutsche Gesellschaft für Chirurgie* 2007; 392:611-5.

Valentine W, Massi-Benedetti M, Tan M, Yates J, Dormandy J, Williams R, Foos V, Brändle M, Palmer A, Bottomley J, PROactive Study Group. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK. *Diabetic medicine : a journal of the British Diabetic Association* 2007; 24:982-1002.



Müller-Stich B, Brändle M, Binet F, Warschkow R, Lange J, Clerici T. To autotransplant simultaneously or not -- can intraoperative parathyroid hormone monitoring reliably predict early postoperative parathyroid hormone levels after total parathyroidectomy for hyperplasia?. *Surgery* 2007; 142:47-56.

Brändle M, Azoulay M, Greiner R. Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland. *International journal of clinical pharmacology and therapeutics* 2007; 45:203-20.

Roffi M, Brändle M, Robbins M, Mukherjee D. Current perspectives on coronary revascularization in the diabetic patient. *Indian heart journal* 2007; 59:124-36.

Sze L, Schmid C, Bloch K, Bernays R, Brändle M. Effect of transsphenoidal surgery on sleep apnoea in acromegaly. *Eur J Endocrinol* 2007; 156:321-9.

Brändle M. Diabetes - Patient Selection. In: *Textbook of Interventional Cardiology*. 5th Edition Philadelphia, PA: Saunders Elsevier, 2007. ISBN 978-1-4160-4835-0. pp. 23-50.

Schmid C, Brändle M. The influences of hyperprolactinaemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. *Clinical endocrinology* 2006; 65:827-8.

Schmid C, Zwimpfer C, Brändle M, Krayenbühl P, Zapf J, Wiesli P. Effect of thyroxine replacement on serum IGF-I, IGFBP-3 and the acid-labile subunit in patients with hypothyroidism and hypopituitarism. *Clinical endocrinology* 2006; 65:706-11.

Palmer A, Roze S, Valentine W, Ray J, Frei A, Burnier M, Hess B, Spinaz G, Brändle M. Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland. *Swiss medical weekly : official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology* 2006; 136:346-52.

Schmid C, Goede D, Hauser R, Brändle M. Increased prevalence of high Body Mass Index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma. *Swiss medical weekly : official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology* 2006; 136:254-8.

Pavlicek V, Garzoni D, Urech P, Brändle M. Inaccurate self-monitoring of blood glucose readings in patients on chronic ambulatory peritoneal dialysis with icodextrin. *Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association* 2006; 114:124-6.

Forst T, Caduff A, Talary M, Weder M, Brändle M, Kann P, Flacke F, Friedrich C, Pfützner A. Impact of environmental temperature on skin thickness and microvascular blood flow in subjects with and without diabetes. *Diabetes technology & therapeutics* 2006; 8:94-101.

Herman W, Ackermann R, Marrero D, Hamman R, Engelgau M, Zhang P, Sorensen S, Brändle M, Hicks K, Hoerger T, Ratner R. Managing people at high risk for diabetes. *Annals of internal medicine* 2006; 144:66-7; author reply 67-8.

Zhou H, Isaman D, Messinger S, Brown M, Klein R, Brändle M, Herman W. A computer simulation model of diabetes progression, quality of life, and cost. *Diabetes care* 2005; 28:2856-63.

Palmer A, Tucker D, Ray J, Valentine W, Currie C, McEwan P, Brändle M. Insulin pumps: more consultation was needed. *BMJ (Clinical research ed.)* 2005; 331:905-6.

Roffi M, Cattaneo F, Brändle M. Thyrotoxicosis and the cardiovascular system. *Minerva endocrinologica* 2005; 30:47-58.

Herman W, Ratner R, Engelgau M, Ackermann R, Hamman R, Zhang P, Sorensen S, Hicks K, Brändle M, Hoerger T, Diabetes Prevention Program Research Group. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. *Annals of internal medicine* 2005; 142:323-32.

Wiesli P, Bernays R, Brändle M, Zwimpfer C, Seiler H, Zapf J, A Spinas G, Schmid C. Effect of pituitary surgery in patients with acromegaly on adiponectin serum concentrations and alanine aminotransferase activity. *Clinica chimica acta; international journal of clinical chemistry* 2005; 352:175-81.

Wiesli P, Brändle M, Schmid C, Krähenbühl L, Furrer J, Keller U, Spinas G, Pfammatter T. Selective arterial calcium stimulation and hepatic venous sampling in the evaluation of hyperinsulinemic hypoglycemia: potential and limitations. *Journal of vascular and interventional radiology : JVIR* 2004; 15:1251-6.

Brändle M, Herman W. The CORE Diabetes Model. *Current medical research and opinion* 2004; 20 Suppl 1:S1-3.

Tabaei B, Shill-Novak J, Brändle M, Burke R, Kaplan R, Herman W. Glycemia and the quality of well-being in patients with diabetes. *Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation* 2004; 13:1153-61.

Wiesli P, Brändle M, Pfammatter T, Zapf J, Spinas G, Schmid C. Insulin determination by specific and unspecific immunoassays in patients with insulinoma evaluated by the arterial stimulation and venous sampling test. *European journal of endocrinology / European Federation of Endocrine Societies* 2004; 151:123-6.

Wiesli P, Brändle M, Zapf J, Seiler H, Zwimpfer C, Spinas G, Schmid C. Assessment of hyperinsulinaemia at the termination of the prolonged fast. *Clinica chimica acta; international journal of clinical chemistry* 2004; 342:227-31.

Schmid C, Wiesli P, Bernays R, Bloch K, Zapf J, Zwimpfer C, Ghirlanda C, Brändle M. Decrease in sE-selectin after pituitary surgery in patients with acromegaly. *Clinical chemistry* 2004; 50:650-2.

Clerici T, Brändle M, Lange J, Doherty G, Gauger P. Impact of intraoperative parathyroid hormone monitoring on the prediction of multiglandular parathyroid disease. *World journal of surgery* 2004; 28:187-92.

Maier M, Schmid C, Galeazzi R, Krull I, Heitz P, Locher T, Schmid S, Saremaslani P, Komminoth P, Brändle M, Perren A. A novel succinate dehydrogenase subunit B gene mutation, H132P, causes familial malignant sympathetic extraadrenal paragangliomas. *The Journal of clinical endocrinology and metabolism* 2004; 89:362-7.

Schmid C, Brändle M, Zwimpfer C, Zapf J, Wiesli P. Effect of thyroxine replacement on creatinine, insulin-like growth factor 1, acid-labile subunit, and vascular endothelial growth factor. *Clinical chemistry* 2004; 50:228-31.

Ealovega M, Tabaei B, Brändle M, Burke R, Herman W. Opportunistic screening for diabetes in routine clinical practice. *Diabetes care* 2004; 27:9-12.

Brändle M, Zhou H, Smith B, Marriott D, Burke R, Tabaei B, Brown M, Herman W. The direct medical cost of type 2 diabetes. *Diabetes care* 2003; 26:2300-4.

Wiesli P, Brändle M, Brandner S, Kollias S, Bernays R. Extensive spherical amyloid deposition presenting as a pituitary tumor. *Journal of endocrinological investigation* 2003; 26:552-5.

Brändle M, Davidson M, Schriger D, Lorber B, Herman W. Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes. *Diabetes care* 2003; 26:1796-801.

Fricker M, Wiesli P, Brändle M, Schwegler B, Schmid C. Impact of thyroid dysfunction on serum cystatin C. *Kidney international* 2003; 63:1944-7.

Hernan W, Brändle M, Zhang P, Williamson D, Matulik M, Ratner R, Lachin J, Engelgau M, Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program. *Diabetes care* 2003; 26:36-47.

Wiesli P, Brändle M, Schwegler B, Lehmann R, Spinas G, Schmid C. A plasma glucose concentration below 2.5 mmol L<sup>-1</sup> is not an appropriate criterion to end the 72-h fast. *Journal of internal medicine* 2002; 252:504-9.

Coffey J, Brändle M, Zhou H, Marriott D, Burke R, Tabaei B, Engelgau M, Kaplan R, Herman W. Valuing health-related quality of life in diabetes. *Diabetes care* 2002; 25:2238-43.

Vavricka S, Walter R, Brändle M, Ballmer P, Haller A. [Diabetic ketoacidosis and hyperosmolar hyperglycemia. 24 consecutive cases]. *Deutsche medizinische Wochenschrift (1946)* 2002; 127:2441-6.

Brändle M, Spinas G. [Management of cardiovascular risk factors in type 2 diabetes mellitus]. *Therapeutische Umschau. Revue thérapeutique* 2002; 59:415-21.

Brändle M, Pfammatter T, Spinas G, Lehmann R, Schmid C. Assessment of selective arterial calcium stimulation and hepatic venous sampling to localize insulin-secreting tumours. *Clinical endocrinology* 2001; 55:357-62.

Brändle M, Lehmann R, Maly F, Schmid C, Spinas G. Diminished insulin secretory response to glucose but normal insulin and glucagon secretory responses to arginine in a family with maternally inherited diabetes and deafness caused by mitochondrial tRNA(LEU(UUR)) gene mutation. *Diabetes care* 2001; 24:1253-8.

Clerici T, Schmid C, Komminoth P, Lange J, Spinas G, Brändle M. 10 Swiss kindreds with multiple endocrine neoplasia type 1: assessment of screening methods. *Swiss medical weekly : official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology* 2001; 131:381-6.

Imhof A, Schneemann M, Schaffner A, Brändle M. Reactive hypoglycaemia due to late dumping syndrome: successful treatment with acarbose. *Swiss medical weekly : official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology* 2001; 131:81-3.

Brändle M, Schlaeppli M, Schmid C. [Type 2A multiple endocrine neoplasia with cutaneous lichen amyloidosis]. *Schweiz Med Wochenschr* 2000; 130:861.

Brändle M, Schmid C. Galactorrhoea and pituitary mass: a typical prolactinoma?. *Postgraduate medical journal* 2000; 76:232-4.

**Eggenberger C, Brändle M, Galeazzi R, Spinaz G, Schmid C. [Cushing syndrome due to ectopic ACTH secretion: an uncommon case presentation, diagnosis and therapy]. Schweizerische medizinische Wochenschrift 1999; 129:890-5.**

**Brändle M, Amann F, Salomon F. [Type 2 diabetes mellitus and coronary heart disease]. Schweizerische medizinische Wochenschrift 1999; 129:700-6.**

**Brändle M, Galeazzi R, Diener P, Schmid C. Medullary thyroid carcinoma in Graves' disease. Clinical endocrinology 1999; 50:545-6.**

**Brändle M, Galeazzi R, Morant R, Oesterle M. [Osteopenia in beta-thalassemia major]. Schweizerische medizinische Wochenschrift 1996; 126:1867-74.**

**Brändle M, Vernazza P, Oesterle M, Galeazzi R. [Cerebral toxoplasmosis with central diabetes insipidus and panhypopituitarism in a patient with AIDS]. Schweizerische medizinische Wochenschrift 1995; 125:684-7.**

## Projects (20)

### **VitCov Studie**

*Clinical Studies - Jan 25, 2021 - Dec 31, 2021*

*Automatically Closed*

### **Differences in adherence to national target criteria for good disease management in tertiary diabetes care: Challenges and/or unmet needs?**

*Clinical Studies - Nov 1, 2018 - Oct 31, 2019*

*Automatically Closed*

### **TOASST**

*Clinical Studies - Jul 8, 2017 - Jun 8, 2020*

*Automatically Closed*

### **TOASST**

*Clinical Studies - Jul 1, 2017 - Dec 31, 2025*

*Ongoing*

### **CODDI**

*Clinical Studies - Jan 1, 2016 - Oct 31, 2017*

*Completed*

### **LX4211 310**

*Clinical Studies - Oct 10, 2015 - Dec 31, 2017*

*Completed*

### **LUNA Studie**

*Clinical Studies - Jan 21, 2014 - Jan 21, 2014*

*Completed*

### **SUSTAIN**

*Clinical Studies - Dec 1, 2013 - Jan 31, 2015*

*Completed*

### **SENECA - PILOT**

*Clinical Studies - Aug 27, 2013 - Feb 5, 2014*

*Completed*

**Sekretion von Katecholaminen und ihrer methoxylierten Metabolite durch die menschliche Nebenniere und durch Phäochromozytome**

*Clinical Studies - May 30, 2013 - Dec 31, 2020*

*Automatically Closed*

**ORIGINALE**

*Clinical Studies - Nov 19, 2012 - Nov 19, 2016*

*Completed*

**Häufigkeit und klinische Relevanz der pulmonalen Hypertonie bei Patienten mit Hyperthyreose**

*Clinical Studies - Jun 1, 2012 - Dec 31, 2022*

*Completed*

**Opiattherapie und NNR-Insuffizienz**

*Clinical Studies - Jan 1, 2012 - Dec 31, 2022*

*Completed*

**DUAL II**

*Clinical Studies - Dec 24, 2011 - Nov 24, 2012*

*Completed*

**FAPAS Studie**

*Clinical Studies - Dec 15, 2011 - Dec 31, 2013*

*Completed*

**Victoza-Insulin-Studie**

*Clinical Studies - Apr 25, 2011 - Mar 25, 2012*

*Completed*

**Molecular and mutational profiling in Papillary Thyroid Carcinoma with special emphasis on the influence of BRAFV600E Mutation on Tumor Stage, Outcome and nuclear imaging**

*Clinical Studies - Jan 21, 2011 - Dec 30, 2013*

*Completed*

**KIMS**

*Clinical Studies - Jul 25, 2010 - Jul 31, 2012*

*Completed*

**Swiss Diabetes Registry**

*Clinical Studies - Jan 1, 2010 - Jan 1, 2014*

*Automatically Closed*

**ORIGIN**

*Clinical Studies - Sep 1, 2004 - Sep 1, 2008*

*Completed*

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)